Immunome, Inc. (IMNM)
| Market Cap | 2.68B |
| Revenue (ttm) | 6.94M |
| Net Income (ttm) | -212.39M |
| Shares Out | 113.13M |
| EPS (ttm) | -2.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 691,603 |
| Open | 23.36 |
| Previous Close | 23.49 |
| Day's Range | 23.19 - 23.76 |
| 52-Week Range | 7.15 - 27.65 |
| Beta | 2.14 |
| Analysts | Strong Buy |
| Price Target | 32.80 (+38.22%) |
| Earnings Date | May 8, 2026 |
About IMNM
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including I... [Read more]
Financial Performance
In 2025, Immunome's revenue was $6.94 million, a decrease of -23.23% compared to the previous year's $9.04 million. Losses were -$212.39 million, -27.50% less than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price target is $32.8, which is an increase of 38.22% from the latest price.
News
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced...
Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead
Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation of its recovery trend with upside momentum building toward prior highs.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...
Immunome Transcript: Leerink Global Healthcare Conference 2026
Varegacestat, a once-daily gamma secretase inhibitor, showed strong phase III results in desmoid cancer and is on track for FDA submission and potential launch by year-end. The pipeline includes next-gen ADCs, with ROR1 ADC data expected this year, and global commercialization strategies are in place.
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome Transcript: TD Cowen 46th Annual Health Care Conference
Varegacestat demonstrated strong phase III results in desmoid tumors, with NDA submission planned for Q2 2026 and manufacturing readiness confirmed. The pipeline includes three new ADCs targeting solid tumors, a promising radiotherapy program, and a focus on expanding market share and long-term patient benefit.
Immunome to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members o...
Immunome Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The pipeline emphasizes targeted oncology therapies, with a lead gamma secretase inhibitor showing strong phase III results in desmoid tumors and an NDA submission expected soon. The ADC platform is advancing with IM-1021 in phase 1, targeting lymphomas, and a radioligand therapy is set to enter clinical trials.
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...
Immunome Transcript: 44th Annual J.P. Morgan Healthcare Conference
AL102 achieved strong Phase III results in desmoid tumors and is on track for NDA submission in Q2, with potential approval by year-end. The pipeline includes a promising ROR1 ADC, three new solid tumor ADC INDs, and a FAP radioligand, all supported by a strong cash position.
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...
Immunome Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...
Immunome Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced i...
Immunome Transcript: Study Result
The Phase 3 Ringside trial showed varegacestat significantly improved progression-free survival, response rate, and tumor volume reduction in desmoid tumors, with a favorable safety profile and manageable side effects. Regulatory submission is planned for 2026, and commercial preparations are underway.
Immunome's experimental drug meets main goal in late-stage study
Immunome said on Monday its experimental drug met main goal in a late-stage study for patients with a rare type of tumor.
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive top...
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company wi...
Immunome Transcript: Evercore ISI 8th Annual HealthCONx Conference
Major 2025 milestones included advancing AL102 toward phase 3 data and progressing the ADC pipeline, with IM1021 showing early activity and multiple INDs planned for 2026. AL102 aims to outperform OGSIVEO in efficacy and tumor reduction, while the ADC platform focuses on overcoming resistance and safety limitations seen in competitors.
Immunome Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing targeted cancer therapies, with Varegacestat’s phase III data for desmoid tumors expected imminently and a global regulatory submission planned within months. Its next-generation ADC platform is showing promising early clinical results, with multiple new programs set for 2026–2027.
Immunome Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Focused on targeted cancer therapies, the company is advancing varegacestat for desmoid tumors, with phase 3 data expected soon and strong differentiation from existing treatments. The ADC pipeline, led by a ROR1 candidate, aims to set new standards in efficacy and resistance.
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical...
Infinimmune Announces Research Collaboration with Immunome
ALAMEDA, Calif.--(BUSINESS WIRE)-- #antibodies--Infinimmune Announces Research Collaboration with Immunome.
Immunome Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Focused on advancing a robust oncology pipeline, including a phase III gamma secretase inhibitor for desmoid tumors and a proprietary ADC platform targeting novel cancer antigens. Strategic IP protection and innovative payload technology differentiate the approach.